Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tragrisso

- PMLiVE

AZ seeks leg up in antiplatelet market with Brilinta antidote

Reversal agent has been developed by company's biotech subsidiary Medimmune

- PMLiVE

EMA leaderless as tribunal forces Guido Rasi out

Court annuls appointment of executive director due to selection process concerns

EU flag

EU watchdog raps EMA for redacted AbbVie data

Issues over the redaction of clinical study reports

- PMLiVE

Nexium windfall lifts AZ in third quarter

Still to feel effects of generic competition

- PMLiVE

AZ advances immuno-oncology ambitions

Buys imaging company and signs PD-1 collaborations with Pharmacyclics and J&J

Biogen Idec building

EMA starts review of Biogen Idec’s haemophilia A therapy

Elocta already on the market in the US, Canada and Australia

Bristol-Myers Squibb (BMS) building

BMS’ PD-1 blocker Opdivo aces lung cancer trial

41% of treated patients alive after 12 months

- PMLiVE

AZ to work with UK university on drug delivery technologies

Company's staff will also teach parts of courses at The University of Manchester

- PMLiVE

Orphan drugs lead CHMP recommendations

Clinuvel's Scenesse is first drug set for European approval to treat rare intolerance to sunlight

- PMLiVE

EMA offers orphan drug benefits for Ebola research

Incentives to encourage development of new treatments for the virus

AstraZeneca AZ global R&D corporate HQ

AstraZeneca cements links with Cambridge University

Agrees a series of collaborations in areas such as Alzheimer's and multiple sclerosis

EMA expands adverse event reporting website

Opens it up to all nationally-authorised medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links